Related Experiment Video
Updated: Jul 18, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Pralidoxime safety and toxicity in children
Myles Thomas Quail1, Michael Wayne Shannon
1Commonwealth of Massachusetts Department of Public Health, Boston, Massachusetts 02116, USA. Tom.Quail@state.ma.us
Prehospital Emergency Care
|December 16, 2006
Summary
Pralidoxime autoinjectors are rarely associated with adverse drug reactions in children treated for organophosphate poisoning. While rare, mild adverse events were observed, further research is needed to confirm safety in pediatric populations.
Area of Science:
- Pediatric Emergency Medicine
- Clinical Toxicology
- Pharmacovigilance
Background:
- The safety of adult pralidoxime autoinjectors for pediatric use was not well-established before 2000.
- Limited literature since 2000 suggested potential use in extreme pediatric cases.
Purpose of the Study:
- To investigate the occurrence of adverse drug reactions (ADRs) in children receiving pralidoxime.
- To assess the safety profile of pralidoxime in pediatric organophosphate poisoning cases.
Main Methods:
- Conducted a literature search (2001-2004) for U.S. children (≤16 years) receiving pralidoxime.
- Analyzed retrospective TESS exposure data from poison centers (1999-2001).
Main Results:
- Eighty-one children received pralidoxime for organophosphate poisoning.
- Two children (2.5%) expired.
- Three children (3.7%) experienced mild adverse drug reactions.
Conclusions:
- Adverse drug reactions to pralidoxime in children appear to be rare.
- Findings suggest cautious interpretation due to study limitations.
- Further research is necessary to confirm pralidoxime safety in pediatric populations and prehospital settings.
Related Concept Videos
01:26Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:00Drug Toxicity: Overview
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...